Skip to main content

Table 1 Descriptive characteristics of GENOA African Americans

From: Intrinsic and extrinsic epigenetic age acceleration are associated with hypertensive target organ damage in older African Americans

Characteristic

Non-Missing N

Mean (SD) or %

Age at Phase I (years)

1390

58.0 (10.1)

DNAm age at Phase I (years)

1390

55.0 (9.9)

IEAA

1389

0.1 (4.8)

EEAA

1390

0.2 (5.8)

Time between Phases I and II

1390

5.1 (1.3)

Sex

1390

 

 Male

 

28.9%

 Female

 

71.1%

Smoking

1390

 

 Never

 

60.2%

 Former

 

27.6%

 Current

 

12.2%

BMI (kg/m2)

1390

31.7 (6.7)

Systolic BP (mmHg)

1390

138.5 (20.8)

Diastolic BP (mmHg)

1390

79.5 (10.9)

Antihypertensive use

1390

 

 No

 

29.2%

 Yes

 

70.8%

Diabetes

1390

 

 No

 

69.7%

 Yes

 

30.3%

Albuminuria (mg/g)

1390

 

 Normal

 

81.7%

 Microa

 

14.3%

 Macrob

 

4.0%

eGFR (mL/min/1.73m2)

1390

88.9 (21.0)

UACR (mg/g)

1390

68.4 (352.9)

RWT

1352

0.3 (0.1)

LVMI (g/m2.7)

1346

39.3 (10.4)

ABI

1359

1.0 (0.1)

WMH (cm3)c

758

10.6 (11.6)

TIV (cm3)c

766

1373.9 (135.8)

  1. Abbreviations: IEAA Intrinsic epigenetic age acceleration, EEAA Extrinsic epigenetic age acceleration, BMI Body mass index, BP Blood pressure, TIV Total intracranial volume, eGFR Estimated glomerular filtration rate, UACR Urinary albumin to creatinine ratio, LVMI Left ventricular mass index, RWT Relative wall thickness, ABI Ankle-brachial index, WMH White matter hyperintensity, TIV Total intracranial volume
  2. aMicroalbuminuria is defined as 30 mg/g ≤ UACR < 300 mg/g
  3. bMacroalbuminuria is defined as UACR ≥300 mg/g
  4. cWMH and TIV were measured an average of 6.3 years after Phase I
  5. All measures were taken at Phase II unless otherwise noted